CDTX
Cidara Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 4
Consensus Rating "Buy"
MACD Death Cross
Ample Liquidity
Significant Revenue Decline
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CDTX
Cidara Therapeutics, Inc.
A biotech company that develops long-acting therapeutics
6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121
--
Cidara Therapeutics, Inc., originally incorporated in Delaware in December 2012 under the name K2 Therapeutics, Inc., changed its name to Cidara Therapeutics, Inc., in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of new anti-infectives for the treatment of diseases that are fully addressed by current standards of care therapies. CD101 is an echinocandin, a class of mature antifungal agents. The company's initial proprietary product candidate is its new compound, CD101, a therapeutic formulation for severe fungal infections. The company's first product is Alternate CD101 Intravenous, formerly biafungin, a potential once-a-week intravenous, or IV, treatment is being used for the development of treatment and prevention of systemic fungal infections. The company's second product candidate, CD101 for topical use, formerly known as topifungin, is an topical preparation CD101 for the treatment of vulvovaginal candidiasis, or VVC, a common mucosal infection. CD101 topical is the first topical application of echinocandin antifungal agents. In addition, the company has developed a proprietary immunotherapy technology platform, CloudbreakTM, which it uses to create compounds designed to guide a patient's immune cells to attack and destroy infectious diseases caused by pathogens. The company is developing its first cloud-breaking development candidate, C001, for the treatment of invasive aspergillosis, which causes fungal pathogens, Aspergillus infections. The company is evaluating more opportunities to expand its cloud-breaking immune platform, infectious diseases and other areas.
Earnings Call
Q1/2025
Estimate EPS-3.47
Actual EPS-1.66
Estimate Revenue--
Actual Revenue--
Cidara Therapeutics' Q1 2025: Unpacking Contradictions in CD388's Opportunity and Pricing Dynamics
May 19,2025 12:21
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CDTX has released its 2025 Q3 earnings. EPS was reported at -3.1, versus the expected -1.33, missing expectations. The chart below visualizes how CDTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
